Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 4
1952 1
1954 3
1955 2
1957 2
1958 1
1959 3
1960 1
1963 2
1964 1
1965 1
1967 1
1969 1
1970 3
1975 2
1976 1
1978 1
1979 3
1983 3
1984 4
1985 1
1986 1
1987 2
1988 2
1989 3
1990 4
1991 3
1992 10
1993 3
1994 1
1995 4
1996 4
1997 4
1998 5
1999 7
2000 4
2002 6
2003 4
2004 8
2005 7
2006 12
2007 15
2008 11
2009 13
2010 13
2011 10
2012 8
2013 14
2014 15
2015 11
2016 17
2017 19
2018 22
2019 23
2020 26
2021 29
2022 22
2023 16
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Results by year

Filters applied: . Clear all
Page 1
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Ridker PM, et al. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28845751 Free article. Clinical Trial.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
Regulation of Intestinal Inflammation by Dietary Fats.
Basson AR, Chen C, Sagl F, Trotter A, Bederman I, Gomez-Nguyen A, Sundrud MS, Ilic S, Cominelli F, Rodriguez-Palacios A. Basson AR, et al. Among authors: ilic s. Front Immunol. 2021 Feb 2;11:604989. doi: 10.3389/fimmu.2020.604989. eCollection 2020. Front Immunol. 2021. PMID: 33603741 Free PMC article.
Rivaroxaban in patients with a recent acute coronary syndrome.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Mega JL, et al. N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077192 Free article. Clinical Trial.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry.
Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Chioncel O, et al. Eur J Heart Fail. 2019 Nov;21(11):1338-1352. doi: 10.1002/ejhf.1492. Epub 2019 May 24. Eur J Heart Fail. 2019. PMID: 31127678 Free article.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
The globalizability of temporal discounting.
Ruggeri K, Panin A, Vdovic M, Većkalov B, Abdul-Salaam N, Achterberg J, Akil C, Amatya J, Amatya K, Andersen TL, Aquino SD, Arunasalam A, Ashcroft-Jones S, Askelund AD, Ayacaxli N, Sheshdeh AB, Bailey A, Barea Arroyo P, Mejía GB, Benvenuti M, Berge ML, Bermaganbet A, Bibilouri K, Bjørndal LD, Black S, Lyshol JKB, Brik T, Buabang EK, Burghart M, Bursalıoğlu A, Buzayu NM, Čadek M, de Carvalho NM, Cazan AM, Çetinçelik M, Chai VE, Chen P, Chen S, Clay G, D'Ambrogio S, Damnjanović K, Duffy G, Dugue T, Dwarkanath T, Envuladu EA, Erceg N, Esteban-Serna C, Farahat E, Farrokhnia RA, Fawad M, Fedryansyah M, Feng D, Filippi S, Fonollá MA, Freichel R, Freira L, Friedemann M, Gao Z, Ge S, Geiger SJ, George L, Grabovski I, Gracheva A, Gracheva A, Hajian A, Hasan N, Hecht M, Hong X, Hubená B, Ikonomeas AGF, Ilić S, Izydorczyk D, Jakob L, Janssens M, Jarke H, Kácha O, Kalinova KN, Kapingura FM, Karakasheva R, Kasdan DO, Kemel E, Khorrami P, Krawiec JM, Lagidze N, Lazarević A, Lazić A, Lee HS, Lep Ž, Lins S, Lofthus IS, Macchia L, Mamede S, Mamo MA, Maratkyzy L, Mareva S, Marwaha S, McGill L, McParland S, Melnic A, Meyer SA, Mizak S, Mohammed A, Mukhyshbayeva A, Navajas J, Neshevska D, Niaz… See abstract for full author list ➔ Ruggeri K, et al. Among authors: ilic s. Nat Hum Behav. 2022 Oct;6(10):1386-1397. doi: 10.1038/s41562-022-01392-w. Epub 2022 Jul 11. Nat Hum Behav. 2022. PMID: 35817934 Free PMC article.
393 results